Least developed countries vs Rwanda: Antiretroviral therapy coverage for PMTCT
Least developed countries
85.2%
in 2024
Rwanda
99.0%
in 2024
Least developed countries rank
6th
Rwanda rank
5th
Antiretroviral therapy coverage for PMTCT over time
- Least developed countries
- Rwanda
How they compare
Rwanda currently reports 99.0% against 85.2% in Least developed countries, a difference of 13.8%.
That makes Rwanda's figure about 1.2 times Least developed countries's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Rwanda ahead.
Least developed countries ranks 6th and Rwanda ranks 5th of 15 groups.
Rwanda has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Least developed countries | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 16.9% | 35.0% | 18.1% | Rwanda |
| 2010s | 69.9% | 94.3% | 24.4% | Rwanda |
| 2020s | 83.8% | 97.2% | 13.4% | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher antiretroviral therapy coverage for pmtct, Least developed countries or Rwanda?
- Rwanda, at 99.0% against 85.2% in Least developed countries as of 2024.
- What is the difference in antiretroviral therapy coverage for pmtct between Least developed countries and Rwanda?
- 13.8%, with Rwanda ahead.
- How many years of comparable data are there for Least developed countries and Rwanda?
- 25 years are reported by both, from 2000 to 2024.
- How do Least developed countries and Rwanda rank globally for antiretroviral therapy coverage for pmtct?
- Least developed countries ranks 6th and Rwanda ranks 5th of 15 groups.
- Where does this data come from?
- UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).